Adragos Pharma, a globally operating Contract Development and Manufacturing Organisation (CDMO) based in Munich, Germany signed definitive agreements with Sanofi K.K. for the acquisition of a pharmaceutical manufacturing site in Kawagoe, in proximity to Tokyo, Japan.
Adragos Pharma will also enter a long-term supply pact with Sanofi K.K, thereby becoming a strategic partner for Sanofi in the Japanese market. Additionally, Adragos Pharma will bring together new customers to the manufacturing site from Europe, and North America inclusive of the domestic Japanese market. Their second investment in the region, Adragos Pharma will now be positioned amongst the top 3 biggest pureplay CDMOs in Japan.
Sanofi and the German CDMO, Adragos Pharma signed the definitive agreements for the transfer of ownership of one of Sanofi’s manufacturing sites in Japan. The site located in Kawagoe has over 50 years of pharmaceutical manufacturing history. Sanofi’s site manufactured oral solids, visual inspection, and sterile liquids, and conducted packing and retesting services for the Asian and Japanese markets.
Under a long-term supply agreement, Adragos Pharma will further continue to manufacture for Sanofi and become its strategic partner for the Japanese market. Adragos Pharma has considered Japan to be one of the three core markets. The Kawagoe site is headed by a well-experienced site leadership team and features a very well-trained workforce, who will all continue to stay at the site. Adragos Pharma aims to further expand the site’s capabilities and services for Sanofi and its upcoming customers, starting production capabilities in the Japanese market and supporting its mission to facilitate access to affordable, high-quality medication.
Jeremy Goldnadel, International & Europe Cluster Head, Industrial Affairs, Sanofi stated that the company is delighted to partner with Adragos Pharma to continue delivering the highest quality products in the long term and further develop the manufacturing site. It firmly believes that the Kawagoe site with its employees will continue to practice the similar strive for excellence with Adragos Pharma, all the way through a new journey that would bring about the most value to their customers and patients in Japan.
Noting the acquisition as a key pillar in building a globally leading CDMO, Dr. Andreas Raabe, CEO at Adragos Pharma, stated that the team is very gratified and honored to further strengthen their excellent relationship with Sanofi. Japan is positioned amongst the largest and most alluring global pharma markets, nevertheless, CDMO activities are relatively burgeoning. With Kawagoe, the company offers tremendous capabilities to its domestic and international consumers.
Marco Gorgas, CTO at Adragos Pharma, stated that the firm is deeply impressed with the site’s workforce and capabilities, which will offer a solid platform for future growth. Gorgas added that Sanofi and its new customers can rely on their full commitment to offering a reliable supply of affordable and exceptional products for the patients. The company has not disclosed the detailed terms of the transaction. The transaction is subject to customary provisions guidelines.
About Adragos
Adragos Pharma is a globally operating CDMO headquartered in Munich, Germany. Its stated objective is to expand its existing production system all through acquisitions in Europe, Japan, and North America to achieve a worldwide leading position within the next few years and set new standards for data centricity and customer service. Adragos Pharma is supported by FSN Capital, a leading Northern European private equity firm, and Prange Group, a diversified leading German family office in its buy-and-build growth approach. Adragos Pharma at present operates three production sites in France, Japan, and Germany.
About Sanofi
Sanofi is an innovative global healthcare company. A limited liability firm unified under the laws of France with securities listed on Euronext Paris, the U.S., and France Nasdaq Global Select Market (Nasdaq). The team spans some 100 countries and is dedicated to transforming the exercise of medicine by working to change the impractical into the viable. The company provides potentially life-changing treatment options and life-saving vaccine protection to millions of people worldwide while placing sustainability and social responsibility at the center of their aspirations.
